Top

Published in:

Open Access 10-02-2024 | Lymphoma | Original Article

Bone marrow biopsy in geriatric patients above the age of 85 years: invaluable or unnecessary? A retrospective analysis

Authors: Kailun David Zhang, Edgar Jost, Jens Panse, Reinhild Herwartz, Katharina Lindemann-Docter, Danny Jonigk, Kim Kricheldorf, Anja Köchel, Nicolas Sauerbrunn, Tim H. Brümmendorf, Steffen Koschmieder, Susanne Isfort

Published in: Annals of Hematology | Issue 4/2024

Abstract

Bone marrow biopsy (BMB) is a well-established diagnostic tool for various hematological, oncological, and other medical conditions. However, treatment options for geriatric patients (pts) facing these diseases are often constrained. In this single-center, retrospective analysis we assessed the diagnostic value of BMB in geriatric pts aged ≥ 85 years and examined its impact on therapeutic decisions. We examined 156 BMB procedures in 129 pts, extracting data from the electronic patient records and applying descriptive statistical methods. Nearly half of the primary diagnostic procedures (26; 44.1%) resulted in a modification of the initially suspected diagnosis. Notably, 15 (25.4%) of these procedures, led to changes in both the diagnosis and planned interventional treatment. Among the 15 follow-up procedures (36.6%), disease progression was initially suspected based on symptoms, but BMB results excluded such progression. In lymphoma staging biopsies, only 2 (3.6%) prompted a change in therapeutic intervention. Importantly, no BMB-related complications, such as bleeding, infection or nerve damage, were reported. Median survival after BMB was 16.1 months across all pts, yet it varied based on the diagnosis and comorbidity score. The survival of pts with a change in therapy based on BMB results did not significantly differ from those who did not undergo a therapy change. In conclusion, BMB proved to be generally safe and beneficial in this geriatric cancer patient cohort beyond the age of 85 years. However, the advantages of lymphoma staging in this patient population warrant further consideration.

United Nations, Department of Economic and Social Affairs (2020) World population ageing 2019. https://doi.org/10.18356/6a8968ef-en

Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, O’Mahony MS, Maughan TS, Parmar M, Langley RE, Investigators F, National Cancer Research Institute Colorectal Cancer Clinical Studies G (2011) Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 377(9779):1749–1759. https://doi.org/10.1016/S0140-6736(11)60399-1CrossRefPubMedPubMedCentral

Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, Andre M, Fournier M, Gaulard P, Tilly H, Grouped’Etude des Lymphomes de l’Adultei (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 12(5):460–468. https://doi.org/10.1016/S1470-2045(11)70069-9CrossRefPubMed

Saiz-Rodriguez M, Labrador J, Cuevas B, Martinez-Cuadron D, Campuzano V, Alcaraz R, Cano I, Sanz MA, Montesinos P (2021) Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis. Cancers (Basel) 13(22). https://doi.org/10.3390/cancers13225677

Saito Z, Fujita K, Okamura M, Ito T, Yamamoto Y, Kanai O, Hashimoto M, Nakatani K, Sawai S, Mio T (2021) Efficacy and safety of immune checkpoint inhibitors in patients with non-small cell lung cancer aged 80 years or older. Cancer Rep (Hoboken) 4(6):e1405. https://doi.org/10.1002/cnr2.1405CrossRefPubMed

Oberic L, Peyrade F, Puyade M, Bonnet C, Dartigues-Cuilleres P, Fabiani B, Ruminy P, Maisonneuve H, Abraham J, Thieblemont C, Feugier P, Salles G, Bijou F, Pica GM, Damaj G, Haioun C, Casasnovas RO, Farhat H, Le Calloch R, Waultier-Rascalou A, Malak S, Paget J, Gat E, Tilly H, Jardin F (2021) Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older. J Clin Oncol 39(11):1203–1213. https://doi.org/10.1200/JCO.20.02666CrossRefPubMed

Nebhan CA, Cortellini A, Ma W, Ganta T, Song H, Ye F, Irlmeier R, Debnath N, Saeed A, Radford M, Alahmadi A, Diamond A, Hoimes C, Ramaiya N, Presley CJ, Owen DH, Abou Alaiwi S, Nassar A, Ricciuti B, Lamberti G, Bersanelli M, Casartelli C, Buti S, Marchetti P, Giusti R, Filetti M, Vanella V, Mallardo D, Macherla S, Sussman TA, Botticelli A, Galetta D, Catino A, Pizzutilo P, Genova C, Dal Bello MG, Kalofonou F, Daniels E, Ascierto PA, Pinato DJ, Choueiri TK, Johnson DB, Marron TU, Wang Y, Naqash AR (2021) Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: A multicenter international cohort study. JAMA Oncol 7(12):1856–1861. https://doi.org/10.1001/jamaoncol.2021.4960CrossRefPubMed

Merli F, Cavallo F, Salvi F, Tucci A, Musuraca G, Nassi L, Merli M, Tani M, Gini G, Ferrari A, Molinari AL, Liberati AM, Conconi A, Matteucci P, Bari A, Scalone R, Ferrero S, Zanni M, Mammi C, Luminari S (2020) Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi. J Geriatr Oncol 11(1):37–40. https://doi.org/10.1016/j.jgo.2019.06.020CrossRefPubMed

Leroy V, Gerard E, Dutriaux C, Prey S, Gey A, Mertens C, Beylot-Barry M, Pham-Ledard A (2019) Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma. Cancer Immunol Immunother 68(4):545–551. https://doi.org/10.1007/s00262-019-02298-9CrossRefPubMed

10.

Peyrade F, Bologna S, Delwail V, Emile JF, Pascal L, Ferme C, Schiano JM, Coiffier B, Corront B, Farhat H, Fruchart C, Ghesquieres H, Macro M, Tilly H, Choufi B, Delarue R, Fitoussi O, Gabarre J, Haioun C, Jardin F (2017) Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Lancet Haematol 4(1):e46–e55. https://doi.org/10.1016/S2352-3026(16)30171-5CrossRefPubMed

11.

Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J, Van Hazel GA, Robinson BA, Broad A, Ganju V, Ackland SP, Tebbutt NC (2012) Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine. Bevacizumab Mitomycin C Ann Oncol 23(6):1531–1536. https://doi.org/10.1093/annonc/mdr488CrossRefPubMed

12.

Krug U, Koschmieder A, Schwammbach D, Gerss J, Tidow N, Steffen B, Bug G, Brandts CH, Schaich M, Rollig C, Thiede C, Noppeney R, Stelljes M, Buchner T, Koschmieder S, Duhrsen U, Serve H, Ehninger G, Berdel WE, Muller-Tidow C (2012) Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia–a randomised SAL pilot study. PLoS One 7(12):e52695. https://doi.org/10.1371/journal.pone.0052695ADSCrossRefPubMedPubMedCentral

13.

Le Clef Q, Menter T, Tzankov A (2019) Our approach to bone marrow biopsies in cytopenia. Pathol Res Pract 215(7):152447. https://doi.org/10.1016/j.prp.2019.152447CrossRefPubMed

14.

Bain BJ (2006) Morbidity associated with bone marrow aspiration and trephine biopsy - a review of UK data for 2004. Haematologica 91(9):1293–1294PubMed

15.

Bain BJ (2005) Bone marrow biopsy morbidity: review of 2003. J Clin Pathol 58(4):406–408. https://doi.org/10.1136/jcp.2004.022178CrossRefPubMedPubMedCentral

16.

Bain BJ (2004) Bone marrow biopsy morbidity and mortality: 2002 data. Clin Lab Haematol 26(5):315–318. https://doi.org/10.1111/j.1365-2257.2004.00630.xCrossRefPubMed

17.

Bain BJ (2003) Bone marrow biopsy morbidity and mortality. Br J Haematol 121(6):949–951. https://doi.org/10.1046/j.1365-2141.2003.04329.xCrossRefPubMed

18.

McGoldrick NP, Green C, Connolly P (2012) Gluteal compartment syndrome following bone marrow biopsy: a case report. Acta Orthop Belg 78(4):548–551PubMed

19.

Lowenthal RM, Taylor BV, Jones R, Beasley A (2006) Severe persistent sciatic pain and weakness due to a gluteal artery pseudoaneurysm as a complication of bone marrow biopsy. J Clin Neurosci 13(3):384–385. https://doi.org/10.1016/j.jocn.2005.03.027CrossRefPubMed

20.

Khakwani M, Srinath S, Pratt G, Moss P (2019) A rare complication of bone marrow aspiration and trephine biopsy: Staphylococcus aureus osteomyelitis and septicaemia. Br J Haematol 184(1):7. https://doi.org/10.1111/bjh.15630CrossRefPubMed

21.

Morotti A, Barozzino MC, Guerrasio A (2016) rare bone marrow biopsy complication: A challenging case of Sacroiliitis and Staphilococcus Aureus Sepsis. Clin Pract 6(1):823. https://doi.org/10.4081/cp.2016.823CrossRefPubMedPubMedCentral

22.

Houtman D, Barten DG, Laurent-de Gast AN (2017) A woman with inguinal pain after a bone marrow biopsy. Ned Tijdschr Geneeskd 161:D952PubMed

23.

Berber I, Erkurt MA, Kuku I, Kaya E, Kutlu R, Koroglu M, Yigit A, Unlu S (2014) An unexpected complication of bone marrow aspiration and trephine biopsy: arteriovenous fistula. Med Princ Pract 23(4):380–383. https://doi.org/10.1159/000358173CrossRefPubMedPubMedCentral

24.

Sarigianni M, Vlachaki E, Chissan S, Klonizakis F, Vetsiou E, Anastasiadou KI, Ioannidou-Papagiannaki E, Klonizakis I (2011) Haematoma caused by bone marrow aspiration and trephine biopsy. Hematol Rep 3(3):e25. https://doi.org/10.4081/hr.2011.e25CrossRefPubMedPubMedCentral

25.

Al Zahrani Y, Peck D (2016) Median sacral artery injury following a bone marrow biopsy successfully treated with selective trans-arterial embolization: a case report. J Med Case Rep 10:42. https://doi.org/10.1186/s13256-016-0827-5CrossRefPubMedPubMedCentral

26.

Wan Jamaludin WF, Mohamed Mukari SA, Abdul Wahid SF (2013) Retroperitoneal hemorrhage associated with bone marrow trephine biopsy. Am J Case Rep 14:489–493. https://doi.org/10.12659/AJCR.889274CrossRefPubMedPubMedCentral

27.

Mistry R, Gokhman I, Bastani R, Gould R, Jimenez E, Maxwell A, McDermott C, Rosansky J, Van Stone W, Jarvik L, Group UC (2004) Measuring medical burden using CIRS in older veterans enrolled in UPBEAT, a psychogeriatric treatment program: a pilot study. J Gerontol A Biol Sci Med Sci 59(10):1068–1075. https://doi.org/10.1093/gerona/59.10.m1068CrossRefPubMed

28.

Linn BS, Linn MW, Gurel L (1968) Cumulative illness rating scale. J Am Geriatr Soc 16(5):622–626. https://doi.org/10.1111/j.1532-5415.1968.tb02103.xCrossRefPubMed

29.

Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Dohner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370(12):1101–1110. https://doi.org/10.1056/NEJMoa1313984CrossRefPubMed

30.

Salvi F, Miller MD, Grilli A, Giorgi R, Towers AL, Morichi V, Spazzafumo L, Mancinelli L, Espinosa E, Rappelli A, Dessi-Fulgheri P (2008) A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc 56(10):1926–1931. https://doi.org/10.1111/j.1532-5415.2008.01935.xCrossRefPubMed

31.

Gordon MJ, Churnetski M, Alqahtani H, Rivera X, Kittai A, Amrock SM, James S, Hoff S, Manda S, Spurgeon SE, Choi M, Cohen JB, Persky D, Danilov AV (2018) Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. Cancer 124(15):3192–3200. https://doi.org/10.1002/cncr.31554CrossRefPubMed

32.

Federal Statistical Office of Germany, Robert-Koch Institute: Gesundheitsberichtserstattung des Bundes. 2002 and 2022. https://www.gbe-bund.de/gbe/!pkg_olap_tables.prc_set_page?p_uid=gast&p_aid=69135500&p_sprache=D&p_help=2&p_indnr=524&p_ansnr=27031407&p_version=6&D.001=1000001&D.003=42

33.

34.

Tefferi A (2021) Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 96(1):145–162. https://doi.org/10.1002/ajh.26050CrossRefPubMed

35.

Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, Hillmen P, Ireland R, Kulasekararaj A, Mufti G, Snowden JA, Samarasinghe S, Wood A, Marsh JC, British Society for Standards in H (2016) Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 172(2):187–207. https://doi.org/10.1111/bjh.13853CrossRefPubMed

36.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405. https://doi.org/10.1182/blood-2016-03-643544CrossRefPubMed

37.

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstocker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120(12):2454–2465. https://doi.org/10.1182/blood-2012-03-420489CrossRefPubMedPubMedCentral

38.

Schmidt A, Bernhardt C, Burkle D, Fries S, Hannig CV, Jentsch-Ullrich K, Josting A, Kreher S, Reiser M, Steinmetz HT, Tesch H, Terner S, Schulte A, Crodel CC, Palandri F, Heidel FH (2023) Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany. J Cancer Res Clin Oncol 149(10):7197–7206. https://doi.org/10.1007/s00432-023-04669-3CrossRefPubMedPubMedCentral

39.

Manion EM, Rosenthal NS (2008) Bone marrow biopsies in patients 85 years or older. Am J Clin Pathol 130(5):832–835. https://doi.org/10.1309/AJCPXPPIF21LJJCZCrossRefPubMed

40.

Han EJ, O JH, Yoon H, Ha S, Yoo IR, Min JW, Choi JI, Choi BO, Park G, Lee HH, Jeon YW, Min GJ, Cho SG (2022) Comparison of FDG PET/CT and Bone Marrow Biopsy Results in Patients with Diffuse Large B Cell Lymphoma with Subgroup Analysis of PET Radiomics. Diagnostics (Basel) 12(1). https://doi.org/10.3390/diagnostics12010222

41.

Vishnu P, Wingerson A, Lee M, Mandelson MT, Aboulafia DM (2017) Utility of bone marrow biopsy and aspirate for staging of diffuse large b cell lymphoma in the era of positron emission tomography with 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose integrated with computed tomography. Clin Lymphoma Myeloma Leuk 17(10):631–636. https://doi.org/10.1016/j.clml.2017.06.010CrossRefPubMed

42.

Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgues JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G (2022) Polatuzumab vedotin in previously untreated diffuse large B-Cell Lymphoma. N Engl J Med 386(4):351–363. https://doi.org/10.1056/NEJMoa2115304CrossRefPubMed

43.

Weidmann E, Neumann A, Fauth F, Atmaca A, Al-Batran SE, Pauligk C, Jager E (2011) Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol 22(8):1839–1844. https://doi.org/10.1093/annonc/mdq671CrossRefPubMed

44.

Hamilton R, Andrews I, McKay P, Leach M (2014) Loss of utility of bone marrow biopsy as a staging evaluation for Hodgkin lymphoma in the positron emission tomography-computed tomography era: a West of Scotland study. Leuk Lymphoma 55(5):1049–1052. https://doi.org/10.3109/10428194.2013.821201CrossRefPubMed

45.

El-Galaly TC, d’Amore F, Mylam KJ, de Nully BP, Bogsted M, Bukh A, Specht L, Loft A, Iyer V, Hjorthaug K, Nielsen AL, Christiansen I, Madsen C, Johnsen HE, Hutchings M (2012) Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 30(36):4508–4514. https://doi.org/10.1200/JCO.2012.42.4036CrossRefPubMed

Title: Bone marrow biopsy in geriatric patients above the age of 85 years: invaluable or unnecessary? A retrospective analysis
Authors: Kailun David Zhang
Edgar Jost
Jens Panse
Reinhild Herwartz
Katharina Lindemann-Docter
Danny Jonigk
Kim Kricheldorf
Anja Köchel
Nicolas Sauerbrunn
Tim H. Brümmendorf
Steffen Koschmieder
Susanne Isfort
Publication date: 10-02-2024
Publisher: Springer Berlin Heidelberg
Keywords: Lymphoma
Myelodysplastic Syndrome
Published in: Annals of Hematology / Issue 4/2024
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-024-05650-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2024

Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM)

Correction to: One disease, two faces: clonally-related AML and MPDCP with skin involvement

Clinical characteristics and treatment outcomes of Asian patients with T-cell large granular lymphocytic Leukemia: a single-center analysis of 67 cases

Acute myeloid leukemia with rare recurring translocations—an overview of the entities included in the international consensus classification

BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma

Transfusion of blood components in pediatric age groups: an evidence-based clinical practice guideline adapted for the use in Egypt using ‘Adapted ADAPTE’

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials